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Abstract
The use of medicines during pregnancy deserves special attention from dentists due to the potential risks to fetal develop-
ment. The prescription of antimicrobial drugs during this period must be based not only on the etiology of the disease but 
also on the drug’s effect on the embryo, which may be toxic, possibly leading to irreversible lesions. Interest in studies 
of the teratogenic effects of drugs increased in response to reports of the high incidence of phocomelia in patients treated 
with thalidomide. Although teratogenicity has long been known, pregnant women today are still exposed to this risk. The 
effects of drugs depend on the level of susceptibility of the fetus and on the period of exposure during pregnancy. In this 
context, and considering the paucity of studies on this subject in dentistry, the aim of this review was to offer an up-to-date 
compilation of data on the antimicrobial drugs most frequently used during pregnancy and the effects of their use.
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Introduction
The use of antimicrobials has increased steadily since the dis-
covery of penicillin (1). Numerous drugs have been developed 
since then, few of which were considered potentially toxic (2). 
Interest in studies of the teratogenic effects of drugs during 
pregnancy has increased since 1961, when the high incidence 
of phocomelia among patients treated with thalidomide was 
discovered (2). Although teratogenicity has long been known, 
pregnant women are still exposed to this risk (3).
Previous studies have found that 99% of pregnant women 
were prescribed at least one drug during pregnancy. The 
average consumption of drugs, excluding vitamins and su-
pplements, is estimated to be 1.3 drugs per woman (3,4). In 
Brazil, this average is 4.2 drugs per woman during pregnancy, 
and the use of just one drug during pregnancy is 83% (2,5).
In this context, and in view of the scant studies on this subject 
in the field of dentistry, the purpose of this review was to make 
an up-to-date compilation of data on antimicrobial drugs 
commonly prescribed by dentists for pregnant women.
Methodology
This study consisted of a systematic bibliographic review of 
national and international researches involving the antimi-
crobials most frequently used in dentistry and their effects 
during pregnancy. 
The bibliographic review involved journals and books contai-
ning data from the MEDLINE, LILACS (Latin-American and 
Caribbean Health Sciences), SciELO (Scientific Electronic 
Library Online - Brazil), and Scopus databases. This review 
found a paucity of studies published from 1990 to 2006. The 
Publication Types: Review 
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research was conducted using the keywords: “antibiotics and 
pregnancy”, “antimicrobials and pregnancy”, “antibacterial 
agents and pregnancy”, and “puerperium”.
Bibliographic review
The precise determination of the safe use of antimicrobial 
drugs in dentistry is not easy, particularly due to the ethical 
implications involved in studies on humans (2,5). The availa-
ble data have been garnered through clinical observations of 
similar cases and cause-effect correlations in fetal abnormali-
ties (6). Numerous studies have been based on researches with 
animals. However, they require careful evaluation due to the 
morphofunctional differences among species and considering 
the real correlation to adverse effects on humans (2,3).
Pregnancy is a dynamic state characterized by physiological 
and pharmacokinetic alterations that affect two organisms 
simultaneously (3,7-9). The effects of drugs depend on the 
level of susceptibility of the fetus and on the drug, as well as 
on the period of exposure during pregnancy. The genotype of 
mother and child may also contribute to higher susceptibility 
or resistance to a certain pharmacological agent. Also, the 
level of immaturity of essential organs may lead to different 
responses, according to the age of the fetus (2,8,10,11).
The use of teratogenic substances during the preimplantation 
phase that occurs in the first two weeks after fertilization may 
determine failure in embryonic fixation, leading to fetal death; 
therefore, the occurrence of teratogenesis is very rare (2,12, 
13). Throughout this period, drugs such as metronidazol, 
erythromycin estolate and tetracycline must be avoided (7, 
11,12,13). 
During the phase of organogenesis, malformations are more 
frequently observed and are considered the main alterations 
associated with the use of some antimicrobials drugs. These 
drugs are responsible for the worst prognoses, such as con-
genital abnormalities, intrauterine growth retardation and 
teratogenesis (2,12,14). Throughout this period, antimetabolic 
drugs, especially those with activity on nucleic acid such as 
sulfamethoxazole, are not recommended because they are 
associated with several major malformations such as neural 
tube and cardiovascular defects (15).
During the last phase of embryonic development (the fetal 
phase), which comprises the 25th week until the end of preg-
nancy, exposure to drugs may lead to reduced body weight, 
functional disorders and carcinogenesis. These effects are 
correlated to high cell replication and immature biotransfor-
mation mechanism (8,14,16). During this phase, drugs such as 
sulfonamide, quinolone, erythromycin estolate, tetracycline 
and chloramphenicol are not recommended (12,16).
Other aspects that must be observed in pregnancy involve 
maternal physiological transformations (4,10,14). Most 
changes derive from hormonal alterations, which are charac-
terized mainly by increased estrogen, progesterone, human 
chorionic gonadotropin (beta HCG) and prolactine levels 
(4,9,12,14). During pregnancy, metabolic alterations also 
occur, e.g., protein metabolism, lipid and glucose profiles, 
alterations in respiratory dynamics, changes in eating habits, 
gestational gingivitis, gastroesophageal reflux, constipation 
and immunological alterations (4,9,12). 
The intake of liquids is also altered in this phase, and the 
plasmatic volume may be up to 50% above the normal 
average (2,4,10,13). According to some authors, to maintain 
therapeutic concentrations of a drug during pregnancy may 
require higher doses and lower intervals between intakes, 
due to increased volemia and higher cardiac deficit (4,6). 
These physiological alterations, allied to the pharmacoki-
netic characteristics of pregnancy, may even lead to failure 
of the therapy (7,8,16). In early pregnancy, gastrointestinal 
disorders, nausea and emesis associated with estrogen-related 
peristalsis may interfere with the absorption of antimicrobials 
taken orally (9,13). 
The pharmacokinetic characteristics of drugs are of great 
importance in the maternal-fetal context (8,10,16,17). Among 
these characteristics, low molecular weight, lipophilic charac-
teristics and the ability to cross through tissue compartments 
by concentration-dependent diffusion, and high degree of 
plasma-protein binding (e.g., clindamycin, doxicyclin, oxa-
cyclin, chloramphenicol and erythromycin) are particularly 
important. Increased delivery from plasma to other biological 
sites may occur, augmenting renal elimination (7-10).
Other important aspects involve biotransformation. Special 
attention should focus on plasma concentrations of drugs, 
particularly when a drug is prescribed concomitantly with 
an enzyme-inducing agent that maximizes its metabolism 
(9,10). With regard to the elimination of antimicrobials, 
the increased renal blood flow and glomerular filtration 
rate resulting from augmented cardiac deficit lead to higher 
drug filtration rates. The level of unaltered drugs excreted 
by urine, except for some types of penicillin, increases (7, 
9,17). Based on the aforementioned effects, it is clear that 
the ideal antimicrobial drug for pregnant woman should not 
pass through the placental barrier, and it is desirable to have 
conclusive clinical evidence of its safety is (6,10). 
On the other hand, the antimicrobial resistance of microor-
ganisms has been increasing at alarming rates worldwide. In 
view of this problem, it is sometimes not possible to prescribe 
a drug based solely on clinical evidence of its safety and 
effectiveness (18,19). Nevertheless, most of the antimicro-
bials used in dentistry are reportedly safe, allowing for their 
prescription during pregnancy (3,7,17,19).
In situations where evidence-based therapeutic choice is not 
possible, maternal-fetal monitoring is essential (6). Profes-
sionals today follow the recommendations of the Food and 
Drug Administration (FDA) regarding the safety of drugs for 
use during pregnancy, dividing them into five categories of 
teratogenic risk: A, B, C, D and X (1,7,16).
Category A – This category includes drugs and substances 
that have been tested through controlled studies in women. 
These studies have shown no risk to the fetus during the first 
semester of pregnancy and the possibility of damage to the 
fetus is remote.
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Category B – Studies with animals have shown that the 
substance offers no risk to the fetus, but no controlled studies 
have been made in humans to verify possible adverse effects 
on the fetus. This category includes drugs that have shown 
adverse effects on animal fetuses, but controlled studies on 
humans did not reveal risks to the fetus. 
Category C – Studies with animals have indicated that the-
se drugs may have teratogenic or/and toxic effects on the 
embryo, but no controlled studies involving women have 
been made. A drug also falls into this category when there 
are no available controlled studies involving either animals 
or humans.
Category D – There is evidence of risk to the human fetus, 
but the benefits in certain situations, e.g., serious diseases or 
life-threatening situations with no other alternative therapy, 
may justify the use of these drugs during pregnancy. 
Category X – Studies in animals or humans have demonstra-
ted that the drug causes alterations of the fetus or have shown 
evidence of increased risk to the fetus, based on experiments 
in both animals and humans. The risk to the fetus outweighs 
any benefit. 
In dentistry, the use of antimicrobials is indicated in several 
cases, including presurgical prophylaxis and in the endodontic 
treatment of periapical abscesses (18-20). Due to the mag-
nitude of the subject under discussion, we will discuss here 
only the factors that may influence the selection of a drug, 
and the available evidence of the bacterial infections most 
frequently observed during pregnancy. 
1. Penicillin 
Penicillins are bactericides that belong to the betalactamic 
group. Their mechanism of activity is based on the inhibition 
of bacterial cell wall synthesis through inactivation of the 
transpeptidase enzyme (17,21).
The penicillins most frequently used in dentistry are classified 
as natural penicillin: crystalline penicillin G (endovenous-
EV), penicillin G procaine (intramuscular-IM), and penicillin 
G benzatine (IM); and semisynthetic penicillin: phenoxy-
methylpenicillin (via oral-VO), betalactamase-resistant 
penicillin: oxacillin, cloxacillin and methicillin; and amino-
penicillin: ampicillin, amoxicillin (3,21).
With regard to their activity spectrum, they generally act on 
Gram-positive rods. Oxacillin, methicillin and dicloxacin, 
and also larger spectrum penicillin (such as amoxicillin as-
sociated with clavulanic acid and ampicillin associated with 
sulbactam) are effective on Gram-negative microorganisms 
(3,17,21).
Undoubtedly this antimicrobial drug is the most indicated for 
pregnant women, since it has highly selective toxicity (14, 
17). Penicillin can be described as safe and is classified as 
category B by the FDA. Few side effects are described, and 
the most important reactions are gastrointestinal disorders and 
hypersensitivity (1,22). The occurrence of hypersensitivity 
reactions may vary from 1% to 10% of patients and may 
be fatal for 0.02% of cases. Acute reactions occur after 22 
minutes following intake, and are characterized by urticaria, 
angiodema, bronchospasm, hypotension or anaphylactic 
shock.  Immediate reactions occur between 30 minutes and 48 
hours after penicillin intake and are represented by urticaria, 
angiodema, bronchospasm, wheezing and local inflamma-
tion. Late reactions occur after 72 hours of penicillin intake, 
with characteristic symptoms: skin reactions, exfoliative 
dermatitis, serious stomatitis and acute glossitis (22,23). In 
dentistry, its use is indicated in endodontics, implantology, 
surgery and for bacterial endocarditis prophylaxis, according 
to the American Heart Association (1,19).
2. Cephalosporins
These drugs also belong to the betalactamic group and show 
similar activity and resistance mechanisms as those of the 
penicillins. They are subdivided into generations: first gene-
ration: cefazolin, cefalexin, cefadroxil, and cefradine; second 
generation: cefuroxime, cefprozile, and cefmetazol; third 
generation: cefotaxime, cefdinir, ceftriaxone, cefoperazone 
and ceftazidime; fourth generation: cefepime, and cefpiroma 
(21,23). The cephalosporins, in addition to penicillin, are one 
of the antimicrobial drugs most frequently indicated during 
pregnancy and are classified as category B by the FDA (7, 
21). Like penicillin, cephalosporins show low occurrence of 
adverse reactions, except for hypersensitivity, which affects 
10% of patients with hypersensitivity to penicillin due to 
cross-hypersensitivity (23).
3. Macrolides
Erythromycin, clarithromycin, roxithromycin, and azithromy-
cin are macrolides that interfere with the bacterial synthesis 
of leucine, by their action on 50S subunits of ribosomes, 
inhibiting the translocation of t-RNA (21,24). They are 
bacteriostatic, but may be bactericide, depending on the 
microbial species and inoculum microorganisms involved 
in the infectious process, as well as the drug concentration 
in the infected area (21,25).
They show similar spectrum of activity as that of penicillin. 
They are effective against Gram-positive, anaerobic and a 
wide spectrum of Gram-negative microorganisms (24). Their 
toxicity is low due to the absence of subunit 50S in human 
cells (12). However, erithromycin may cause cholestatic he-
patitis, general hepatoxicity and gastrointestinal alterations, 
mainly in estolate form (24). Erythromycin is classified as 
category B by the FDA and the base form is considered the 
best form for use during pregnancy (1). In dentistry, besides 
erithromycin associated with metronizadol, azithromycin and 
clarithromycin are indicated for penicillin-allergic patients, 
treatment of endodontic infections after root canal deconta-
mination, and periapical abscesses (19,22). It is considered 
the third choice for the prophylaxis of bacterial endocarditis 
(18).
4. Lincosamines
In this group, clindamycin is the only drug that is indicated 
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for pregnant women in dentistry (19,21). It is bacteriostatic, 
although it may have bactericidal effects in high dosages. It 
is effective against anaerobic and a wide spectrum of Gram-
positive microorganisms (21,26). Its mechanism of activity 
is the bacterial inhibition of protein biosynthesis through 
activity on ribosome 50S and inhibition of peptidil transferase 
in tRNA translocation (26). 
The drugs of this group have a spectrum of activity similar to 
that of penicillin, but they are active against betalactamase-
producing strains (7,21,26). The adverse reactions most 
frequently observed are chronic diarrhea and pseudomem-
branous colitis (27).
There is no evidence of teratogenic risks related to this drug, 
which is classified as category B by the FDA (3,6,14). In 
dental practice, it belongs to the group of drugs that can be 
prescribed for penicillin-allergic patients (19,21). This group 
is indicated in clinical situations such as osteitis or other bone 
infections caused by anaerobic microorganisms. It is highly 
effective in the treatment of abscesses because it is macro-
molecular, easily phagocyted by macrophages and leukocytes 
(19,20). Moreover, it can also reach the gingival fluid, main-
taining higher concentrations when compared to the minimum 
inhibitory concentration (MIC) for Gram-negative anaerobic 
bacteria associated with periodontal disease. This feature 
eliminates the need for association with metronidazol during 
pregnancy (7,20). They are usually selected for the treatment 
of advanced and chronic periodontal diseases, particularly 
those refractory to penicillin (18).
5. Tetracyclines
These drugs are bacteriostatic with a wider spectrum of 
activity than penicillin and macrolides. They block bacterial 
protein synthesis by binding to 30S unit ribosomes and inhibit 
RNA aminoacyl transferase. They are active against Gram-
positive, Gram-negative, microaerophilic and anaerobic 
microorganisms (1,27).
The high affinity of this drug group to bivalent ions (such 
as calcium) affects bone development, inducing significant 
reductions in gingival colagenase and also high periodontal 
bone loss. Moreover, it may cause dental alterations such as 
dentin pigmentation and dental enamel hypoplasia (6,21). It 
shows direct interference in mineralized tissue, formation of 
dental germs in permanent teeth and deciduous fetal dentition 
(7,21). Because of these effects, they are classified as category 
D by the FDA and are considered unsuitable for use during 
pregnancy. Tetracycline may cause reactions such as nausea, 
epigastric pain, abdominal distention, oral ulcerative lesions, 
diarrhea, hepatic and renal disorder and photosensitivity (1, 
12,14).
6. Metronidazol
Metronidazol is an essentially antiprotozoan prodrug (28). It 
is widely used in dentistry in association with other antimi-
crobials such as betalactamics and macrolides. Metronidazol 
is the third most frequently prescribed antimicrobial drug in 
dentistry during pregnancy (3,7,29). It has a narrow spectrum 
of activity, acting against anaerobic and microaerophilic mi-
croorganisms, with no effect on aerobic microorganisms (21, 
29). Its mechanism of activity involves decrease of the level 
of nicotinamide adenine dinucleotide (NADH) synthesis and 
reduced level of nicotinamide adenine dinucleotide phosphate 
(NADPH) due to its interference in the hydrogen pathway 
(28). In dentistry, it is prescribed in association with amoxici-
llin for the treatment of advanced and/or acute periodontitis, 
mainly for necrotizing ulcerative gingivitis (NUG) (21,29). 
It is also indicated for the treatment of acute infections such 
as pericoronaritis and periapical abscesses (18). This drug 
shows few adverse effects if used during a limited period. It 
may cause blood dyscrasias, gastrointestinal disorders, and a 
metallic taste in the mouth (12,18,29). It is not recommended 
during the first trimester of pregnancy, although it is classified 
as a relatively safe antiprotozoan, and is classified as category 
B by the FDA (1,29).
Final Considerations
There are no definitive and complete answers for the safe use 
of antimicrobials during pregnancy. However, the available 
information provides the dentist with a choice of various 
therapeutic and prophylactic options within relatively safe 
limits. The prescription of drugs during pregnancy must be 
evaluated carefully, weighing the risks versus benefits for 
both fetus and mother. Antimicrobial drugs with toxic poten-
tial should therefore be prescribed by the physician only if 
the infectious disease is life-threatening and there is no other 
choice for its treatment.
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